Oropharyngeal Cancer

P2, N=36, Recruiting, Medical University of South Carolina | Initiation date: Jul 2026 --> Oct 2026

Continuous oncogene expression was required for lesion maintenance, as doxycycline withdrawal reversed the proliferative phenotype, indicating a dynamic and reversible process...These findings demonstrate that identical oncogenic signals-HPV16 E6/E7 expression and PI3K activation-produce distinct premalignant outcomes depending on epithelial context. This work highlights the critical role of local microenvironmental factors in HPV-driven carcinogenesis and provides a platform to identify tissue-specific therapeutic vulnerabilities in HPV-associated cancers.

Furthermore, HPV ctDNA but not HPV16 E6 antibody levels were positively associated with disease burden as determined by N-category, overall stage, and by tumor volume (ctDNA vs. volume, r = 0.48 p = 6.4e-12; E6 vs. volume, r = -0.079 p = 0.26). Overall, this is the largest cohort to compare HPV serology and HPV ctDNA results in OPC, and these findings highlight the potential for ctDNA to augment future strategies for blood-based early detection of HPV+ OPC.

P1/2, N=51, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed

P=N/A, N=50, Not yet recruiting, National University Hospital, Singapore

P2, N=31, Active, not recruiting, Wake Forest University Health Sciences | Trial primary completion date: Jun 2026 --> Sep 2026

Although anti-Yo/PCA-1-associated rapidly progressive cerebellar syndrome has rarely been reported in patients with SCC, tumor expression of CDR2L has not been demonstrated in such cases. This case supports the diagnostic value of examining tumor CDR2L expression in anti-Yo/PCA-1-associated rapidly progressive cerebellar syndrome with non-breast/non-gynecologic malignancies, especially SCC.

P1/2, N=35, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting

P3, N=826, Not yet recruiting, Aveta Biomics, Inc.

The combination of metformin and pembrolizumab was well tolerated with mild GI-associated AEs and promising activity warranting further investigation in a randomized trial.

P1/2, N=120, Not yet recruiting, National Cancer Institute (NCI)

This case highlights that unilateral tonsillar enlargement may rarely represent metastatic lung cancer, particularly in the appropriate clinical context and advanced disease. Histopathology with immunohistochemistry is essential to distinguish metastatic SCLC from primary tonsillar malignancy. Early otolaryngologic assessment and biopsy remain the key diagnostic steps in this rare presentation.